Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Life After DLBCL Treatment

At a Glance

After finishing DLBCL treatment, you will shift to a surveillance schedule with regular physical exams rather than routine PET scans. A personalized survivorship care plan is essential to monitor for late effects like heart issues and help manage emotional challenges like scanxiety.

Finishing treatment for Diffuse Large B-Cell Lymphoma (DLBCL) is a major milestone, but it often brings a new and unexpected set of emotions. Transitioning from the intense “doing” phase of treatment to the “watch and wait” phase of survivorship can feel like losing a safety net [1]. Understanding the roadmap for life after DLBCL can help you move forward with confidence.

The Surveillance Roadmap

Once you achieve a complete remission, your medical team will shift to a surveillance schedule. For the first two years—when the risk of relapse is highest—you will likely see your oncologist every 3 to 6 months for a physical exam and a review of your symptoms [2][3].

As you move past the two-year mark, your visits will become less frequent. By five years out, most survivors transition to a long-term survivorship plan, often managed by a primary care doctor who works in consultation with your oncologist [2][3].

Why “No Scans” Can Be Good News

Many patients are surprised to learn that doctors do not recommend routine PET/CT scans for survivors who have no symptoms [4].

  • False Positives: PET scans are highly sensitive and can “light up” for many reasons other than cancer, such as a recent infection, inflammation, or even a minor injury [5][6]. These “false alarms” often lead to unnecessary anxiety and invasive biopsies [7][8].
  • Radiation Risk: Repeated CT scans involve cumulative radiation exposure, which can increase the risk of developing a secondary cancer later in life [4].
  • Symptom Awareness: Research shows that the majority of DLBCL relapses are found because the patient noticed a new symptom or a doctor found something during a physical exam—not through a “surprise” finding on a routine scan [9][10].

Symptoms to report immediately: New lumps or swelling, drenching night sweats, unexplained fevers, or unintentional weight loss [3][11].

Long-Term Health Monitoring

While the treatment for DLBCL is life-saving, it can sometimes have “late effects” that appear months or years later.

  • Cardiac Health: The drug doxorubicin can cause a slow weakening of the heart muscle over time [12]. You may need periodic echocardiograms to monitor your heart’s pumping strength (ejection fraction) even years after treatment ends [13].
  • Mental Health: Many survivors experience scanxiety—a wave of intense anxiety that peaks in the days leading up to a follow-up appointment or while waiting for test results [14][15]. Acknowledging this as a real medical phenomenon can help you seek support, such as mindfulness-based interventions or counseling, to manage the stress [16][17].

Building Your Survivorship Plan

Before you leave your oncologist’s regular care, ask for a written Survivorship Care Plan. This document should include:

  1. A summary of all chemotherapy drugs and doses you received [2].
  2. A clear schedule for future screenings (like heart tests or mammograms) [2].
  3. A list of “late effects” specific to your treatment [2].
  4. Resources for managing fatigue, neuropathy, and emotional health [18][19].

Survivorship is not about waiting for the cancer to come back; it is about taking active steps to protect your health and well-being after you have beaten it [2][18].

You can return to the Home Page to review all the topics.

Common questions in this guide

How often will I see my oncologist after finishing DLBCL treatment?
For the first two years after achieving remission, you will likely see your oncologist every 3 to 6 months for a physical exam and symptom review. After five years, most survivors transition to long-term care managed by a primary care doctor.
Why don't doctors recommend routine PET scans after DLBCL treatment?
Routine PET scans are not recommended for survivors without symptoms because they often produce false alarms from harmless inflammation or infections. Repeated scans also expose you to unnecessary radiation, which can increase the risk of secondary cancers over time.
What are the late side effects of DLBCL treatment?
Late effects can appear months or years after treatment and may include heart muscle weakening from chemotherapy drugs like doxorubicin, as well as lingering fatigue or neuropathy. Regular monitoring, such as echocardiograms, helps track your long-term cardiac health.
What symptoms should I report to my doctor after DLBCL remission?
You should immediately report any new lumps or swelling, drenching night sweats, unexplained fevers, or unintentional weight loss. Research shows that relapses are most often discovered because a patient noticed these specific symptoms.
What is scanxiety and how can I manage it?
Scanxiety is the intense fear or worry many cancer survivors feel leading up to follow-up appointments or while waiting for test results. Acknowledging this medical phenomenon is the first step, and using mindfulness, counseling, or planned treats can help manage the stress.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific treatment, what is my long-term schedule for heart monitoring (echocardiograms)?
  2. 2.What is the plan for my survivorship care, and which of my doctors will manage my follow-up visits?
  3. 3.If I notice a new lump or symptom, how quickly should I contact you, and what tests will we do first?
  4. 4.Are there specific secondary cancers I should be screened for because of the chemotherapy or radiation I received?
  5. 5.How do I distinguish between normal post-treatment fatigue and symptoms that might indicate the lymphoma is returning?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Scanxiety: a scoping review about scan-associated anxiety.

    Bui KT, Liang R, Kiely BE, et al.

    BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

    PMID: 34039571
  2. 2

    Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma.

    Brooks ED, Fang P, Pinnix CC

    The British journal of radiology 2021; (94(1127)):20210360 doi:10.1259/bjr.20210360.

    PMID: 34378402
  3. 3

    Evolution of therapy for limited stage diffuse large B-cell lymphoma.

    Rojek AE, Smith SM

    Blood cancer journal 2022; (12(2)):33 doi:10.1038/s41408-021-00596-z.

    PMID: 35210407
  4. 4

    Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis.

    Berger MD, Trelle S, Büchi AE, et al.

    Haematologica 2021; (106(7)):1923-1931 doi:10.3324/haematol.2020.249680.

    PMID: 32554560
  5. 5

    Benign Histiocyte-Rich Pseudotumor Developing Postchemotherapy and Mimicking Residual Disease.

    Singh AP, Murray GP, Pandey S

    Case reports in pathology 2020; (2020()):4674103 doi:10.1155/2020/4674103.

    PMID: 32695545
  6. 6

    Benign thyroid nodule mimicking residual disease on positron emission tomography/computed tomography in a patient with concurrent thyroid and gastric diffuse large B-cell lymphoma: the value of ultrasound-guided biopsy.

    Tatoğlu MT, Özsoy MS

    Journal of ultrasound 2026; doi:10.1007/s40477-026-01122-2.

    PMID: 41663627
  7. 7

    Diffuse Large B-Cell Lymphoma With a Background of Extensive Granulomatous Inflammation: A Potential Pitfall for Misdiagnosis.

    Hassanzadeh S, Mackrides N, Rastegar S, Nejati R

    Cureus 2021; (13(7)):e16198 doi:10.7759/cureus.16198.

    PMID: 34367801
  8. 8

    Prostate tuberculosis mimicking malignancy on 18F-FDG PET/CT in a patient with diffuse large B-cell lymphoma: A case report.

    Bai M, Yu Q, Yuan L, et al.

    Medicine 2024; (103(22)):e38296 doi:10.1097/MD.0000000000038296.

    PMID: 39259096
  9. 9

    Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.

    Basit A, Siddiqui N, Muzaffar N, et al.

    JPMA. The Journal of the Pakistan Medical Association 2016; (66(4)):380-6.

    PMID: 27122261
  10. 10

    Integration of PET in DLBCL.

    Lewis KL, Trotman J

    Seminars in hematology 2023; (60(5)):291-304 doi:10.1053/j.seminhematol.2023.12.003.

    PMID: 38326144
  11. 11

    Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: Update on a Rare Disease and Potential Diagnostic Pitfalls.

    Zanelli M, Sanguedolce F, Zizzo M, et al.

    Current oncology (Toronto, Ont.) 2022; (29(2)):956-968 doi:10.3390/curroncol29020081.

    PMID: 35200580
  12. 12

    Anthracycline Cardiotoxicity in a Patient with Diffuse Large B-Cell Lymphoma: A Case Report.

    Teixeira da Silva F, Morais Passos R, Esteves A, et al.

    Cureus 2020; (12(10)):e11038 doi:10.7759/cureus.11038.

    PMID: 33214965
  13. 13

    Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

    Coiffier B, Sarkozy C

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):366-378 doi:10.1182/asheducation-2016.1.366.

    PMID: 27913503
  14. 14

    Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

    Bui KT, Kiely BE, Dhillon HM, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

    PMID: 34333717
  15. 15

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  16. 16

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  17. 17

    The effect of mindfulness-based interventions on biomarkers in cancer patients and survivors: A systematic review.

    Matiz A, Scaggiante B, Conversano C, et al.

    Stress and health : journal of the International Society for the Investigation of Stress 2024; (40(4)):e3375 doi:10.1002/smi.3375.

    PMID: 38259050
  18. 18

    Fatigue, Neuropathy and Psychological Distress and Their Association With Health-Related Quality of Life in Survivors of Diffuse Large B-Cell Lymphoma: A Prospective Cohort Study and Comparison With a Normative Population.

    Neppelenbroek SIM, Ekels A, Kersten MJ, et al.

    Hematological oncology 2025; (43(6)):e70151 doi:10.1002/hon.70151.

    PMID: 41204681
  19. 19

    Persistent symptoms of fatigue, neuropathy and role-functioning impairment among indolent non-Hodgkin lymphoma survivors: A longitudinal PROFILES registry study.

    Ekels A, van de Poll-Franse LV, Posthuma EFM, et al.

    British journal of haematology 2022; (197(5)):590-601 doi:10.1111/bjh.18139.

    PMID: 35365860

This page provides information about life after DLBCL treatment for educational purposes only. Always consult your oncologist or primary care doctor to develop a personalized survivorship care plan.

Get notified when new evidence is published on Diffuse large B-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.